Evidence map›Paper›PMID 31585987›Full record

ArticleMolecular & cellular proteomics : MCP2019

Fast and Accurate Bacterial Species Identification in Urine Specimens Using LC-MS/MS Mass Spectrometry and Machine Learning.

Florence Roux-Dalvai, Clarisse Gotti, Mickaël Leclercq, Marie-Claude Hélie, Maurice Boissinot, Tabiwang N Arrey, Claire Dauly, Frédéric Fournier, Isabelle Kelly, Judith Marcoux and 3 more

Open access · hybridAbstract readValidation Study
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 74 citations in OpenAlex.

  1. Deep Learning-Based Rapid Identification ofRisk management and healthcare policy · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Discrimination of CommonJournal of the American Society for Mass Spectrometry · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Florence Roux-DalvaiProteomics platform, CHU de Québec - Université Laval Research Center, Québec City, Québec, Canada.
Clarisse GottiProteomics platform, CHU de Québec - Université Laval Research Center, Québec City, Québec, Canada.
Mickaël LeclercqComputational Biology Laboratory, CHU de Québec - Université Laval Research Center, Québec City, Québec, Canada.
Marie-Claude HélieCentre de Recherche en Infectiologie de l'Université Laval, Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Québec City, Canada.
Maurice BoissinotCentre de Recherche en Infectiologie de l'Université Laval, Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Québec City, Canada.
Tabiwang N ArreyThermo Fisher Scientific, Bremen, Germany.
Claire DaulyThermo Fisher Scientific, Bremen, Germany.
Frédéric FournierProteomics platform, CHU de Québec - Université Laval Research Center, Québec City, Québec, Canada.
Isabelle KellyProteomics platform, CHU de Québec - Université Laval Research Center, Québec City, Québec, Canada.
Judith MarcouxProteomics platform, CHU de Québec - Université Laval Research Center, Québec City, Québec, Canada.
Julie Bestman-SmithLaboratoire de microbiologie-infectiologie, CHU de Québec-Université Laval, pavillon Hôpital de l'Enfant-Jésus, Québec City, Québec, Canada.
Michel G BergeronCentre de Recherche en Infectiologie de l'Université Laval, Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Québec City, Canada; Département de microbiologie-infectiologie et d'immunologie, Faculté de médecine, Université Laval, Québec City, Québec, Canada.
Arnaud DroitProteomics platform, CHU de Québec - Université Laval Research Center, Québec City, Québec, Canada; Computational Biology Laboratory, CHU de Québec - Université Laval Research Center, Québec City, Québec, Canada; Département de Médecine Moléculaire, Faculté de médecine, Université Laval, Québec City, QC, Canada. Electronic address: arnaud.droit@crchuq.ulaval.ca.
Université Laval · CAThermo Fisher Scientific (Germany) · DEHôpital de l'Enfant-Jésus · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fast identification of microbial species in clinical samples is essential to provide an appropriate antibiotherapy to the patient and reduce the prescription of broad-spectrum antimicrobials leading to antibioresistances. MALDI-TOF-MS technology has become a tool of choice for microbial identification but has several drawbacks: it requires a long step of bacterial culture before analysis (≥24 h), has a low specificity and is not quantitative. We developed a new strategy for identifying bacterial species in urine using specific LC-MS/MS peptidic signatures. In the first training step, libraries of peptides are obtained on pure bacterial colonies in DDA mode, their detection in urine is then verified in DIA mode, followed by the use of machine learning classifiers (NaiveBayes, BayesNet and Hoeffding tree) to define a peptidic signature to distinguish each bacterial species from the others. Then, in the second step, this signature is monitored in unknown urine samples using targeted proteomics. This method, allowing bacterial identification in less than 4 h, has been applied to fifteen species representing 84% of all Urinary Tract Infections. More than 31,000 peptides in 190 samples were quantified by DIA and classified by machine learning to determine an 82 peptides signature and build a prediction model. This signature was validated for its use in routine using Parallel Reaction Monitoring on two different instruments. Linearity and reproducibility of the method were demonstrated as well as its accuracy on donor specimens. Within 4h and without bacterial culture, our method was able to predict the predominant bacteria infecting a sample in 97% of cases and 100% above the standard threshold. This work demonstrates the efficiency of our method for the rapid and specific identification of the bacterial species causing UTI and could be extended in the future to other biological specimens and to bacteria having specific virulence or resistance factors.

Indexed as

Machine LearningBacteriaBacterial ProteinsBacteriuriaChromatography, LiquidHumansPeptidesProteomicsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTandem Mass SpectrometryBacterial ProteinsPeptidesbacteriaLC-MS/MSmachine learningMicrobiologySWATH-MStandem mass spectrometrytargeted mass spectrometryurine analysis

Identifiers

PMID31585987
PMCPMC6885708
OpenAlexW2978053195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.